International Rx Shortages Summit Urges New Purchasing Models
This article was originally published in PharmAsia News
Value of continuous supply should be factor in reimbursement decisions, an International Pharmaceutical Federation report suggests.
You may also be interested in...
The heavily concentrated sterile injectable manufacturing industry is creating roadblocks to the success of the Accelerated Recovery Initiative; GPhA predicts crisis will linger for years to come.
What's in – and what fell out of – the massive US stimulus package.
Early versions of US Congress's coronavirus relief bill contained a number of policies that would have benefited drug firms, but they didn't make it into the final bill. However, the $2 trillion package does provide pharmaceutical companies with relief from the threat of drug pricing reform until after the 2020 elections.